Drugs /

idh2 inhibitor ag-221

Back to Drugs List

Overview

NCI Definition [1]:
An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, AG-221 specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; It initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.

Clinical Trials

View Clinical Trials for idh2 inhibitor ag-221

Idh2 inhibitor ag-221 has been investigated in 6 clinical trials, of which 6 are open and 0 are closed. Of the trials investigating idh2 inhibitor ag-221, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).

IDH2 Mutation, IDH1 Mutation, and IDH2 Codon 140 Missense are the most frequent biomarker inclusion criteria for idh2 inhibitor ag-221 clinical trials.

Acute myeloid leukemia and myelodysplastic syndromes are the most common diseases being investigated in idh2 inhibitor ag-221 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Idh2 Inhibitor Ag-221
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating idh2 inhibitor ag-221 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
idh2 inhibitor ag-221, ag-221, cc-90007
NCIT ID [1]:
C111573

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.